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Improving the physicochemical properties and oral bioavailability of quetiapine fumarate (QF) enabling enhanced antipsychotic
attributes are the main aims of this research. The freeze dried solid dispersion strategy was adopted using nicotinamide (NIC)
as highly soluble coformer. The prepared dispersions were characterized using scanning electron microscopy (SEM) differential
scanning calorimetry (DSC), Fourier transform infrared spectroscopy (FTIR), and X-ray diffraction (XRD). Static disc intrinsic
dissolution rate and ex vivo diffusion through intestinal tissues were conducted and compared to pure quetiapine fumarate. The
results demonstrated a highly soluble coamorphous system formed between quetiapine fumarate and nicotinamide at 1 : 3 molar
ratio through H-bonding interactions. The results showed >14-fold increase in solubility of QF from the prepared dispersions.
Increased intrinsic dissolution rate (from 0.28 to 0.603mg cm−2min−1) and faster flux rate through duodenum (from 0.027 to
0.041mg cm−2 h−1) and jejunum (0.027 to 0.036mg cm−2 h−1) were obtained. The prepared coamorphous dispersion proved to be
effective in improving the drug solubility and dissolution rate and ex vivo diffusion. Therefore, binary coamorphous dispersions
could be a promising solution tomodify the physicochemical properties, raise oral bioavailability, and change the biopharmaceutics
classification (BCS) of some active pharmaceutical ingredients.
1. Introduction
Quetiapine fumarate (QF) is a dibenzothiazepine antipsy-
chotic drug used in treatment of schizophrenia and mania
associated with type I bipolar disorders [1]. The drug has
a relatively short half-life (6 hr) and undergoes extensive
first-pass metabolism. The high frequency of administration
of quetiapine (2–4 times daily) often results in numerous
side effects including panic attacks, dyspnea, and swelling
of lips and face [2]. Quetiapine is marketed under the
brand name Seroquel in different strengths (25–300mg)
and shown to be effective up to a dose of 750mg/day [3].
Quetiapine pharmacokinetics may change when concomi-
tantly administered with some drugs such as ketoconazole,
phenytoin, or rifampicin which affect the activity of CYP3A4
enzymes [4]. Quetiapine has high affinity to serotonin 5-
HT2 than dopamine receptors which makes it suitable for
successful control of psychotic symptoms associated with
Parkinson’s disease without worsening of body movements
[5]. Quetiapine is soluble in acidic pH (2–4); however, due
to its low water solubility over the physiological pH and
high permeability, it was classified as BCS class II drug [6].
Therefore, solid state modification approaches which will
increase its water solubility are expected also to improve its
bioavailability and enable bypassing hepatic metabolism if
administered in suitable dosage form such as orodispersible
or sublingual tablets or films.The increased solubility by new
formulation will enable development of new and predictable
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quality oral and/or parenteral sustained release dosage forms
of the drug.
Stabilized amorphous solid dispersions of poorly soluble
active ingredients are considered new emerging technology
for improvement of water solubility and bioavailability for
biopharmaceutics classification system (BCS) class II drugs.
Amorphous polymeric glass solutions were used for long
time as the favorable system for improving the solubility,
dissolution rate, and stabilization of amorphous drugs [7, 8].
However, these types of systems are hygroscopic and more
liable to reduction of glass transition temperature (𝑇𝑔) and
recrystallization upon storage [9–11]. Also, large amounts
of polymers are often needed to produce effective systems.
In addition a predetermined miscibility of the drug with
the selected polymer is required [12]. All these challenging
problems make it hard to manufacture amorphous disper-
sions [13–15]. As more promising alternative to polymers,
low molecular weight excipients that could interact with the
drug and lower the melting point and increase the 𝑇𝑔 such
as sugars, amino acids, and hydrotropic organic acids are
currently used for drug amorphization [9, 16, 17].
Although the above-mentioned alternatives produced
highly dissolving amorphous systems, yet some systems
showed partial crystallinity observed from remaining unre-
acted drugs or excipients [18, 19]. Binary amorphous sys-
tems that are composed of two pharmacologically related
low molecular weight drugs were recently introduced as
effective coamorphous dispersions (COADs) that overcome
the drawbacks of drug-polymer glass solutions [20, 21].
Many physically stable coamorphous dispersions with high
solubility and dissolution rate were reported in the literature
such as those formed between nateglinide and metformin,
simvastatin and glipizide prepared by ball milling [22, 23],
and naproxen and indomethacin by quench cooling [24].
Other methods such as solvent evaporation or spray drying
could also be used forCOAD formation [25].However, due to
the limited numbers of drug combinations that could interact
at the molecular level with hydrogen or ionic bonding and
produce coamorphous mixtures, other substitutes to one of
the drugs can be made [26].
Amino acids and neutral molecules such as saccharin
or nicotinamide, which are often used for cocrystal for-
mation, can also be applied for COAD preparation using
fast methods of solvent evaporation [15]. In this research
amorphization of QF was undertaken through combination
of with nicotinamide in different molar ratios using hot
and cold approaches for rapid solvent evaporation in an
attempt to enhance oral bioavailability and change the BCS
classification of QF. The produced coamorphous dispersions
were evaluated by solid state characterization, equilibrium
solubility, intrinsic dissolution rate (IDR), and gut perme-
ation compared to the pure drug.
2. Materials and Methods
2.1. Materials. Quetiapine fumarate (QF) was obtained as
free sample from the Jordanian Pharmaceutical Manufac-
turing, Amman, Jordan. Nicotinamide (NIC) was purchased
















Figure 1: Chemical structure of quetiapine fumarate (QF) and nico-
tinamide (NIC).
grades) were purchased from Fluka, UK. Absolute ethanol,
sodium dihydrogen phosphate, sodium hydroxide, and phos-
phoric acid were obtained from Natco Pharma, Hyderabad,
India.
2.2. Preparation of Quetiapine Fumarate-Nicotinamide
Coamorphous Dispersions. The coamorphous dispersions
were prepared by a previously published coprecipitation
method using fast solvent evaporation with some modifi-
cations [27]. Mixtures of QF and NIC based on their molar
mass (441.5 and 122.12 g/mole) and electron donner/acceptor
functional groups (Figure 1) were prepared as shown in
Table 1. Two solvent systems, ethanol and 50% v/v mixture
of ethanol and water (20mL), were used for dissolving the
drug and the conformer using 250mL round bottom flask.
QF dissolves well in ethanol but nicotinamide takes relatively
longer time (30min) on the sonicator before complete
dissolution. As the formulations were dried using freeze
drying, QF was dissolved in 20mL ethanol and separately
nicotinamide was added to an equal volume of water and the
two solutions were admixed just before drying. Freeze drying
(cold evaporation) was applied using Christ freeze dryer
model Alpha 2–4 LD plus (Osterode, Germany).The fast and
controlled cold evaporation increases the chances of contact
and molecular H-bonding interaction between quetiapine
and nicotinamide in concentrated solutions during freeze
drying and could result in amorphous solid dispersions. The
obtained powders were kept under completely dry conditions
using silica gel desiccators until further investigation.
2.3. Scanning ElectronMicroscopy (SEM). Themorphology of
the prepared dispersions was examined using scanning elec-
tron microscopy (Analytical Scanning Microscope, JEOL-
JSM-6510LA, JEOL, Japan). Few specks from each formula-
tion were placed on the carbon stubs and then coated using
a gold sputter (SPI-Module Sputter Coater, SPI Supplies Inc.,
USA) followed by microscopical scanning.
2.4. Differential Scanning Calorimetry (DSC). Samples of
pure QF and NIC and the prepared COAD formulations
(5mg each) were individually filled into aluminum flat
bottomed pans and heated using a simultaneous thermogra-
vimetry-differential scanning calorimeter model STA 449 F3
Jupiter (Nietzsche, Germany) in an atmosphere of nitrogen.
The heating temperature used for the crystalline components
was set between 20 and 300∘Cwith a heating rate 10∘Cmin−1.
The percentage crystallinity 𝑋𝑐 (%) of the prepared samples
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Table 1: Molar ratio composition of QF-NIC coamorphous dispersions.
Formula number Drug (mg) Nicotinamide (mg) ∗∗Mr Solvent system Evaporation method
F1 150 41.49 1 : 1 Ethanol Cold evap.
F2 150 41.49 1 : 1 ∗Eth/W Cold evap.
F3 150 82.98 1 : 2 Ethanol Cold evap.
F4 150 82.98 1 : 2 ∗Eth/W Cold evap.
F5 150 124.47 1 : 3 Ethanol Cold evap.
F6 150 124.47 1 : 3 ∗Eth/W Cold evap.
∗: Eth/W: ethanol/water system 50 : 50 v/v; ∗∗Mr: molar ratio.
was calculated from the enthalpy of fusion of the sample (Δ𝐻)
compared to that of 100% crystalline QT (Δ𝐻0) according to
the following equation [28]:
𝑋𝑐 (%) = ( Δ𝐻Δ𝐻0) × 100. (1)
2.5. Fourier Transform Infrared Analysis (FTIR). Small sam-
ples (2-3mg) of QF and NIC and the prepared COADs
were individuallymixedwith 500mgdry potassiumbromide.
The powder mixtures were compressed into discs under a
pressure of 68.5–103.4MPa using a hydrostatic press. The
infrared spectrum was determined at a scanning range of
1000–3500 cm−1 to detect major characteristic bands in QT
and NIC using a Fourier transform infrared instrument (IR
Prestige-21, Shimadzu, Japan).
2.6. X-Ray Diffraction (XRD). Samples of QF powder and
NIC as well as the COAD formulations were subjected to
X-ray diffraction analysis. A Shimadzu XRD-6000 X-ray
powder diffractometer (Shimadzu, Japan) coupled with a
standard Cu sealed X-ray tube with voltage, current (40 kV
and 40mA), was used to characterize the amorphous or
crystalline state of formulations [29]. Data collection was
performed at 2𝜃 of 5–60∘ in steps of 0.04 and scanning
speed of 0.4 degrees per step. Any change in the crystalline
pattern of the prepared coamorphous dispersions compared
to those of the parent crystalline components was recorded
and evaluated. The index of crystallinity was calculated
according to the ratio of the relative intensity of the sample
(𝐼𝑠) compared to that of the pure crystalline component
(𝐼𝑐) with highest peak [30, 31] according to the following
equation:
% Crystallinity index = (𝐼𝑠𝐼𝑐) × 100. (2)
2.7. Drug Content and Equilibrium Solubility. Samples of
the prepared amorphous dispersions equivalent to 5mg QF
were dissolved in methanol and adjusted to volume using
a standard 50mL volumetric flask. Then, 2mL was taken
and diluted to 10mL with mobile phase. Drug content was
then determined using a photodiode array automated HPLC
analysis systemmodel DGU-20A3/LC-20AT/SIL-20A/CTO-
20A/SPD-M20A (Shimadzu, Japan). For equilibrium sol-
ubility, an amount of the prepared COAD formulations
equivalent to 10mg QF was weighed, placed into 2mL
Eppendorf tubes, and dispersed into 250 𝜇L of distilled water.
The dispersions were then placed on an orbital shaker model
SSM (Stuart, UK) operated at a rate of 300 cycles per min.
The process was continued for 72 hr followed by sonication
for 30 minutes; then, 10𝜇L of the filtered supernatant was
taken and diluted to 10mLwithmethanol.The diluted sample
solutions (𝑛 = 3) were measured by HPLC analysis. The
mobile phase was composed of a mixture of acetonitrile and
0.02M phosphate buffer (50 : 50 v/v) at pH 5.5 adjusted by
0.02M orthophosphoric acid and 0.02M NaOH. The flow
rate was adjusted to 0.8mL/min and the detector wave length
was set at 247 nm [32].
2.8. In Vitro Intrinsic Dissolution Rate Studies. Fixed-disc
method was applied to determine the intrinsic dissolution
rate [33]. In this test, an amount of pure QF (15–20mg) and
an equivalent amount from the selected COAD formulations
(F6) were compressed into small tablets inside aluminum
discs (0.4 cm in diameter) using a manual mini hand press
model MHP-1 (Shimadzu, Japan). The backs of the discs
(𝑛 = 3) were covered with a layer of molted hard paraffin
which were permitted to solidify before immersion into
the dissolution medium. The study was performed using
full automated dissolution system model UDT-804 paddle
dissolution apparatus (Logan, USA) with vessels containing
500mL of phosphate buffer pH 6.8 and rotation speeds
of 50, 75, and 100 rpm in three runs. The temperature of
the media was kept at 37 ± 0.5∘C and at predetermined
time intervals (15, 30, 60, 90, and 120min); samples were
automatically withdrawn and taken for HPLC analysis. The
intrinsic dissolution per unit area of the disc (𝐺𝜔) was
determined as a function of dissolution time and the intrinsic
dissolution rate at infinite rotation speed (𝐾1), that is, at
zero diffusion layer (mg⋅cm−2⋅sec−1), was obtained from the
following equation resulting from plotting the reciprocal of







where 𝐺𝜔 is the intrinsic dissolution rate at 𝜔
(mg⋅cm−2⋅sec−1), 𝐾1 is the intrinsic dissolution rate at
infinite rotation speed (mg⋅cm−2⋅Sec−1), 𝐾2 is a constant,
and 𝜔 is the angular velocity of the disc (radians⋅sec−1).
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Table 2: Thermal analysis and % crystallinity data of QF coamorphous dispersions compared to pure QF and NIC.
Formula
DSC TGA ∗∗Degree of crystallinity (%)











F1 120.10 37.77 152.00 60.14 186.00 67.34 51.00
F2 117.0 31.42 150.60 65.89 184.00 66.93 53.40
F3 120.00 38.70 142.30 21.67 192.60 39.63 73.30
F4 119.50 73.20 ∗NA ∗NA 182.70 48.05 51.50
F5 122.00 128.40 ∗NA ∗NA 199.50 81.69 38.60
F6 117.0 31.0 ∗NA ∗NA 172.00 19.72 24.00
QF 175.40 134.60 ∗NA ∗NA 267.30 — —
NIC 131.80 184.40 ∗NA ∗NA 200.00 — —
∗NA: not available; ∗∗degree of crystallinity (%) calculated from DSC and XRD data.
2.9. Ex Vivo Diffusion Studies. The test was performed to
compare the rate of diffusion of pure QF to that of the
prepared coamorphous dispersions using parts of a fresh
cattle gut. The excised tissues of duodenum and jejunum
were placed on 3.5 cm in diameter plastic diffusion cells (SES
GmbH, Germany) filled to top with 8mL phosphate buffer
(pH 6.8) containing 20mg pure drug or equivalent amount
of the dispersion. The units were placed at the bottom of the
dissolution flasks containing 250mL of the buffer solution.
The paddles were rotated at a speed of 100 rpm and the
temperature was adjusted to 37 ± 0.5∘C. After 0.5, 1, 2, 3, 4, 5,
and 6 hr intervals samples were automatically withdrawn and
taken for HPLC analysis using the same method mentioned
under the drug content and equilibrium solubility section.
Theflux rate 𝐽0 (mg⋅cm−2 hr−1)was obtained from the slope of
the plotted line relating cumulative amount of QF permeated
(mg/cm2) to time (hr) as shown in Figure 8 [35].
3. Results
3.1. Solid State Characterization
3.1.1. DSC Studies. The DSC thermograms of QF and NIC
and the solid dispersions are shown in Figure 2. Characteristic
melting peaks at specific temperatures for QF and NC were
observed at 175.40 and 131.80∘, respectively. The prepared
dispersions showed lower melting temperatures compared to
parent components as displayed in Table 2 containing the
thermal data of QF/NIC coamorphous dispersions. From
Table 2, it could be noticed that two peaks with different
melting points were recorded with various heats of fusion
(Δ𝐻𝑓) from the DSC thermograms of COAD formulations
F1, F2, and F3 whilst single peaks were observed for F4, F5,
and F6. In addition, the sharp decrease in weight was moni-
tored using TGA to indicate the decomposition temperature.
The coamorphous dispersion F6 showed the lowest melting
temperature (117∘C), lowest heat of fusion (Δ𝐻𝑓 = 31 𝜇V/mg),
and decomposition temperature (172∘C). The % crystallinity
was also calculated from theDSC data and the results showed
that the dispersion F6 (1 : 3 Mr) demonstrated the lowest




















Figure 2: DSC thermograms of quetiapine fumarate (QT), nicoti-
namide (NIC), and solid dispersions (F1–F6).
3.1.2. FTIR Studies. FTIR results collected for COAD samples
as well as pure QF and NIC were shown in Figure 3. The
FTIR spectra of NIC indicated the appearance of the charac-
teristic amino group –NH2 symmetric stretching vibrations
at 3379 cm−1 (Figure 3(a)).The C=O stretching also appeared
at 1628 and the –CN stretching vibrations also appeared at
1427 cm−1 which correspond well with the recorded values in
the literature [36]. Other characteristic peaks were noticed
such as the amide band at 1703 and C–O stretching at
1032 cm−1. The FTIR spectra of QF (Figure 3(a)) showed
characteristic peaks at 3313, 3072, 3045, 3012, 2941, 2866,
2870, 2738, 2627, 2347, 1942, 1608, 1568, 1460, 1342, and
1305 cm−1. These peaks also are highly similar to those of
QF Form I polymorph reported in the literature [37]. The
peak at 3313 corresponded to –OH stretching vibrations,
between 3072 and 3130 cm−1 corresponding to –CH aromatic
stretching, whilst –CH aliphatic stretching vibrations were
observed at bands in the region between 2900 and 2940 cm−1.
The aromatic amino (secondary and tertiary) showed absorp-
tion bands between 1300 and 1340 cm−1. The fumarate salt
































































































































































































































































PM 1 : 3
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Figure 3: IR spectra of quetiapine fumarate (QF), nicotinamide (NIC), physical mixtures (PM1–3), and the prepared dispersions (F1–F6).
moiety showed characteristic broad –OH stretching band
which overlapped the –CH stretching region between 300
and 3300 cm−1. The prepared dispersions showed IR bands
shorter than those of parent components and also demon-
strated shifting of some peaks and formation of shoulders in
others as observed in Figures 3(b)–3(d).
3.1.3. XRD Studies. The results of XRD data collected for QF
and NIC and the coamorphous samples are shown in Figures
4 and 5. The highly crystalline QF showed sharp diffraction
lines at 2𝜃 7.3, 9.1, 11.5, 13.2, 14.9, 15.3, 16.2, 17.6, 19.9, 21, 21.7,
22.3, 23.2, 24.8, 25.1, 25.5, 27.1, 28.4, 29.2, 30.6, 33.1, 40.3, and
42.7 degrees. The XRD pattern of NIC showed characteristic
diffraction lines at 2𝜃 values of 21.67∘, 22.63∘, 24.81∘, 26.43∘,
29.91∘, 31.57∘, 33.55∘, 35.88∘, 37.52∘, and 40.28∘ (Figure 4). The
degree of crystallinity was obtained by calculating the ratio
of highest intensity of the solid dispersion sample to that of
the pure crystalline component (Table 2). The XRD patterns
of the dispersions shown in Figure 5 demonstrated lower
intensity (counts 25000–15000) compared to the physical
mixtures (counts >45000). It was observed that sample F6
showed the lowest degree of crystallinity (24.0%) compared
to other dispersions (Table 2).
3.2. Morphology of the Prepared Dispersions Compared to
Parent Components. Scanning electron micrographs of QF
and NIC (Figure 6) demonstrated crystalline shape of both
compounds.The SEM images of the physical mixture showed
small rod like crystals of QF dispersed on large prismatic
crystals of NIC (Figure 6(a)). The binary coamorphous
dispersion F6 (prepared at 1 : 3 molar ratio) showed lack of
defined crystals and appearance of a homogenous dispersion
lacking defined crystals (Figure 6(b)).
3.3. Drug Content and Equilibrium Solubility. The results of
measured equilibrium solubility of the prepared dispersions
obtained after HPLC analysis are shown in Table 3. The
analysis data showed separate and sharp peaks for both
components after injection of the dispersion formulation
(Figure 7) indicating chemical stability of separated QF from
the dispersion. Formula F6 composed of QF and NIC in
1 : 3 molar ratio and prepared by cold evaporation method
demonstrated the highest relative percentage increase in QF
water solubility (1363%) with more than 16-fold increase in
concentration compared to the pure crystalline QF (Table 3).
Formula F5 which had similar composition and evaporation
method to F6 also showed comparable percentage increase
in solubility (1303%). The drug content per 5mg of the
dispersion was calculated for each formula and the results
were found to be comparable to the theoretical content with
insignificant differences between the two (𝑃 > 0.05).
3.4. Intrinsic Dissolution Rate and Ex Vivo Diffusion Studies.
The calculated IDR for pure QF and F6 under the above-
mentioned experimental conditions was found to be 0.284
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Figure 5: X-ray diffractograms of QF-NIC binary coamorphous dispersions (F1–F6).
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F1 569475 10.22 ± 0.102 5.97 497 ± 2.15 3.92 3.94 ± 0.001
F2 578628 10.38 ± 0.337 6.07 507 ± 7.07 3.92 3.89 ± 0.002
F3 963690 17.25 ± 0.080 10.09 909 ± 1.67 3.22 3.18 ± 0.002
F4 792933 14.20 ± 0.076 8.31 731 ± 1.60 3.22 3.21 ± 0.001
F5 1341763 23.99 ± 0.000 14.03 1303 ± 0.00 2.73 2.71 ± 0.003
F6 1398833 25.01 ± 0.032 14.63 1363 ± 0.66 2.73 2.74 ± 0.002
∗QF 92868 1.71 ± 0.035 1.00 0.00 5.00 4.98 ± 0.001
∗Quetiapine fumarate.
(a) (b)




























Figure 7: HPLC chromatograms of QF and NIC and the binary
coamorphous dispersion (F6) after dissolution.
and 0.603mg⋅cm−2⋅min−1, respectively, indicating more than
twofold increase in IDR (Figure 8).
The in vitro diffusion studies through cattle intestinal sec-
tions (duodenum and jejunum) showed superior and faster
diffusion of QF from the dispersion F6 compared to pure QF
(Figures 9(a) and 9(b)). Significantly different (𝑃 < 0.05) flux
rates (𝐽0) for the new dispersion (0.041mg cm−1 h−1) com-
pared to pure QF (0.027mg cm−1 h−1) through duodenum
and (0.036mg cm−1 h−1 to 0.028mg cm−1 h−1) for jejunum
were observed, respectively (Table 4). The data also showed
statistically significant difference in the lag times prior to
commencement of diffusion in both cases in favor of the F6
which showed substantially lower lag times than pure QF and
the reported values in the literature [38].
4. Discussion
The crystalline nature of QF and NIC was confirmed by
sharp melting endotherms which were found to coincide
with those previously published 174∘C [39] and 128–131∘C
[40], respectively.The COAD F6 demonstrated a single short
endotherm with minimum melting temperature indicating
miscibility of the two components [41]. The lowest heat of
fusion (31𝜇V/mg) of this formula among other prepared
COADs may also indicate that such preparation could have
the maximum degree of amorphousness. The IR spectra
showed that the physical mixtures had much shorter peaks
which represent summation of the peaks of QF and NC
with possible interactions (Figure 3). The binary dispersion
samples, however, showed much broader and shorter peaks
and disappearance of some characteristic peaks of QF. The
characteristic peaks at 3313 of QT and 3379 cm−1 of NIC
which represent –OH and –NH stretching vibrations were
found to form a bridge in all binary solid dispersions
(Figures 3(b)–3(d)) indicating H-bonding interactions [42].
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Pure QF 0.027 38.22 0.97 0.028 32.51 0.98
QF-NIC (F6) 0.041 12.15 0.99 0.036 17.72 0.99
y(1/QF) = 28108x + 3.5161
R2 = 0.9974
IDR (QF) = 0.284 mg/min/cm2
QF
QF/NIC
y = 5035.4x + 1.6587
R2 = 0.9727


























IDR (QF-NIC) 0.603 mg/min/cm2=
Figure 8: Plot of the reciprocal of the dissolution rate 1/
G (mg cm−2min−1) versus reciprocal of angular velocity (1/𝜔)
(radians⋅min−1) for determination of IDR from QF and coamor-
phous dispersion F6 (QF-NIC).
Complete disappearance of the characteristic amide peaks
of NIC between 1628 and 1797 cm−1 and C=O asymmetric
stretching of QT salt at 1608 cm−1 have been observed in
almost all dispersions also suggesting H-bonding formation
[43, 44]. The coamorphous sample F6 (Figure 3(d)) showed
shifting of the characteristic peaks of QT from 2735 to
2775 which may support the suggestion of formation of
a true coamorphous dispersion. However, in order to get
another proof of amorphousness, the degree of crystallinity
was calculated from both DSC and X-ray diffraction data.
From the XRD diffraction pattern of QF (Figure 4), it was
shown that the diffraction lines were highly identical to those
observed for QF Form I polymorph cited in the literature
[45]. For nicotinamide also, numerous diffraction lines were
similar to those found in previous research works [46].
For the prepared dispersions (Figure 5) the intensity of the
diffraction lines was highly shortened especially with the
dispersions formulated at 1 : 2 and 1 : 3 molar ratios (F5 and
F6). The lowest degrees of crystallinity (31%) observed for F6
from XRD data and 19% as obtained from DSC data support
the point of view of formation of substantially amorphous or
semicrystalline dispersion [47]. Also the obtained data from
SEM (Figure 6) indicated differences in the shape of the final
coamorphous dispersion being a homogenous aggregate with
undefined edges compared to the clearly identified crystalline
parent components. This dispersion also showed the highest
equilibrium solubility with more than 14-fold increase in
solubility compared to pure crystalline QF.
Therefore, by combining the results of DSC, FTIR, equi-
librium solubility, and XRD data, it becomes clear that
the coamorphous dispersion F6 had a single and short
DSC endotherm, lowest melting temperature, lowest heat
of fusion, shorter and broader IR bands, and lowest degree
of crystallinity. Hence, this QF/NIC (1 : 3Mr) coamorphous
dispersion could be considered the best obtained amorphous
sample with limited crystallinity and consequently it was
selected for in vitro intrinsic dissolution and ex vivo diffusion
studies.
For equilibrium solubility, F6 obtained the largest value
followed by F5 which also support the above hypothesis
of COAD formation. The difference between F6 and F5 is
in the solvent used during preparation of the dispersion,
being ethanol and ethanol/water for F5 and F6, respectively.
This small difference in solubility (both showed >14-fold
increase in solubility) may indicate that the ethanol/water
solvent system has higher support to formation ofH-bonding
during freeze drying leading to formation of a highly soluble
dispersion. The differences in the degrees of crystallinity of
F5 (38.6%) compared to F6 (31%) also confirm that the molar
ratio 1 : 3 was the best between other ratios (Tables 1 and 2).
The importance of the calculation of the intrinsic dis-
solution rate (IDR) of drugs evolves from the roles of both
drug solubility and IDR in the FDA updated determination
of biopharmaceutics classification system of drugs [48, 49].
Although the results of IDR obtained for QF and COAD F6
were found to be a bit lower than the universally suggested
values of IDR (1.00mg⋅cm−2⋅min−1 or 0.017mg⋅cm−2⋅Sec−1)
for drugs classified as highly soluble [38, 50], yet the COAD
system showed promising results by approaching that value
(Figure 8 and Table 4). It is well known that the measurement
of IDR of drugs may vary by variation of the dissolution
conditions such as the media composition, pH, and vol-
ume; however under the same testing conditions differences
between F6 and the reference pure QF were highly evident.
In a similar study but under somewhat different conditions,
quetiapine benzoate IDR was tested in comparison with que-
tiapine hemifumarate (using 900mL degassed water and US
Pharmacopoeia 2 apparatus with device for intrinsic testing,
at 100 rpm). In this test, quetiapine benzoate demonstrated
more than 6-fold increase in IDR compared to quetiapine
hemifumarate [51]. In another study for determination of
IDR, numerous active pharmaceutical ingredients in the salt
Journal of Pharmaceutics 9
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Figure 9: Ex vivo gut permeation profile of quetiapine fumarate (QF) compared to the binary coamorphous dispersion (F6).
form demonstrated IDR values which were not substantially
higher than that observed for the preparedCOAD[52]. In this
study, nicotinamide has been selected as a coformer due to its
high solubility, neutral structure, low melting temperature,
and capability of interacting at molecular level with H-
bonding formation. Such properties were used to obtain
stable coamorphous dispersions. The benefits of increased
solubility and dissolution rate were tested for impact on the
drug diffusion through gut tissues. The results of ex vivo
diffusion through duodenum and jejunum showed faster rate
of diffusion from F6 (>51%) and >28% compared to QF,
respectively (Figure 9 and Table 4). Also, a lower lag time was
observed indicating that the new combination is expected
to have successful role in improving the oral bioavailability
following in vivo administration.
5. Conclusions
The above results of preparation and characterization of
QF/NIC coamorphous dispersions indicated feasibility of the
preparation method and applicability of the dispersion at a
molar ratio of 1 : 3 in improving the physicochemical prop-
erties of QF. The increased solubility by 14-fold and intrinsic
dissolution rate of the drug by 22-fold can be considered an
important achievement that will inevitably result in enhanced
oral bioavailability. This new formulation could also be used
as in-mouth instantly dissolving dosage form which could
enable bypassing of first-pass metabolism. The improved ex
vivo diffusion (high flux and low lag time) observed with
the COAD also provides another proof of success for this
new formulation in raising the expected bioavailability and
possibly changing of the FDA BCS classification of QF.
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